Page last updated: 2024-08-24

fluorodeoxyglucose f18 and axitinib

fluorodeoxyglucose f18 has been researched along with axitinib in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bejot, R; Bhakoo, KK; Goggi, JL; Moonshi, SS	1
Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J	1
Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V	1
Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S	1

Trials

3 trial(s) available for fluorodeoxyglucose f18 and axitinib

Article	Year
Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gastrointestinal Neoplasms; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Withholding Treatment	2014
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Imidazoles; Indazoles; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiopharmaceuticals; Steroids; Treatment Outcome; Young Adult	2016
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated BMC cancer, 2017, 06-02, Volume: 17, Issue:1 Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2017

Other Studies

1 other study(ies) available for fluorodeoxyglucose f18 and axitinib

Article	Year
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome	2013

Article

Year

Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:9

Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome

2013